Lantheus Gains FDA Approval for TAUKLARIFY Tau PET Imaging Agent in Alzheimer's Disease

Lantheus Holdings has cleared a significant regulatory threshold with FDA approval of TAUKLARIFY™ (florquinitau F 18 injection), an F18-labeled tau PET imaging agent whose manufacturing demands will test the readiness of any radiopharmaceutical production network brought into its supply chain. The approval, announced 14 August 2026, covers PET imaging of the brain in adults with cognitive impairment being evaluated for Alzheimer's disease to identify tau neurofibrillary tangle (NFT) pathology.

F18-labeled agents carry an inherent GMP complexity that distinguishes them from conventional small-molecule or biologic products. The isotope's 110-minute physical half-life compresses every stage of the manufacturing cycle, synthesis, quality release, distribution logistics, into a window that leaves no margin for process deviation. Facilities producing TAUKLARIFY must maintain cyclotron infrastructure, validated radiosynthesis modules, and release-testing workflows capable of meeting 21 CFR Part 211 requirements within that compressed timeline. Any site entering Lantheus's commercial supply network will face scrutiny of those controls before product reaches clinical sites.

The approval package rested on two blinded read studies covering more than 500 subjects drawn from three clinical trials. Study 1 (279 subjects) returned Positive Percent Agreement (PPA) of 80–88% and Negative Percent Agreement (NPA) of 98–99%, with inter-reader agreement at a generalized Fleiss' kappa of 0.92. Study 2 (338 subjects) reported PPA of 68–82%. Independent readers were trained on image interpretation and blinded to clinical information and amyloid beta PET results, a study design that will inform how imaging sites structure their own reader qualification and training protocols post-approval.

Lantheus has indicated it will continue supporting Alzheimer's disease therapeutic programs through its Pharma Solutions business while assessing the path toward broader commercial availability. That staged approach is consistent with the supply constraints inherent to short-lived radiopharmaceuticals: geographic reach is bounded by proximity to production sites, and scaling requires either additional licensed manufacturing locations or validated distribution partnerships. QA and regulatory leads at contract manufacturing organisations evaluating entry into this space should anticipate technology transfer packages that address radiosynthesis process validation, sterility assurance for aseptic fill operations, and real-time release testing under accelerated timelines.

TAUKLARIFY carries a limitation of use: its safety and effectiveness have not been established for non-Alzheimer's disease tauopathies, a boundary that will shape both labeling compliance and any future supplemental NDA strategy.

The pace at which Lantheus expands its commercial manufacturing footprint for TAUKLARIFY will serve as a measurable indicator of how the broader radiopharmaceutical sector manages the operational gap between regulatory approval and scalable GMP supply.

Source: Lantheus Holdings, Inc. via GlobeNewswire, 14 August 2026.